Attachments:
FileDescriptionFile size
Download this file (HTL to Present at Bloom Burton Conference FINAL 04.11.19.pdf)11-April-2019-Press-ReleaseHamilton Thorne to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference97 kB

HAMILTON THORNE TO PRESENT AT THE 2019 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

BEVERLY, MA and TORONTO, Ontario – April 11, 2019 -Hamilton Thorne Ltd. (TSX-V:HTL), a leading global provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne Ltd., will present at the upcoming 2019 Bloom Burton & Co. Healthcare Investor Conference.

Date: Wednesday May 1, 2019

Time: 11:00 a.m. Eastern Time

Location: Metro Toronto Convention Centre, 255 Front St W, Toronto, Ontario

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

Investors interested in arranging a meeting with Mr. Wolf during this conference should contact Hamilton Thorne or Bloom Burton & Co.’s conference coordinator.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

David Wolf, President & CEO
Hamilton Thorne Ltd.    
978-921-2050 
ir [AT] hamiltonthorne [DOT] ltd
Michael Bruns, CFO
Hamilton Thorne Ltd.    
978-921-2050 
ir [AT] hamiltonthorne [DOT] ltd
Glen Akselrod
Bristol Investor Relations   
416-737-4467
glen [AT] bristolir [DOT] com

Subscribe to Our Investor Email List